{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-257381","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.965654+00:00","generated_at":"2026-05-17T01:21:05.418247+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially","bullets":["SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.","Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.","FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.","Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.","Cash and investments $473M at Q3 end, up $125M from year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-257381","json":"https://secwatch.observer/filing/0001193125-25-257381.json","markdown":"https://secwatch.observer/filing/0001193125-25-257381.md","text":"https://secwatch.observer/filing/0001193125-25-257381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/0001193125-25-257381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:21:05.418247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}